My Area

Languages:

Therakos e-learning platform

The Therakos Institute

Our Symposia

Arranged in conjunction with key healthcare professionals in the immunotherapy field, our symposia are designed to help keep healthcare professionals informed about the latest advancements in ECP.

If you would like to receive more information, please contact your local Sales Representative.

16 APRIL, 2021

5^th International Chronic GvHD Symposium:
Extracorporeal Photopheresis in the current cGvHD landscape

Virtual Event

Read more

15 MARCH, 2021

NURSE SYMPOSIUM
EBMT 2021:
Therakos ECP Immunomodulation^TM – Getting the most out of your service

Virtual Event

Read more

14 MARCH, 2021

CLINICAL SYMPOSIUM
EBMT 2021:
Calibrating the intensity of GvHD therapy to allow clinical tolerance – A role for ECP Immunomodulation?

Virtual Event

Read more

5 November, 2020

5^th EBMT International Transplant Course: The role of ECP in the treatment of GvHD

Virtual Event

Read more

24 SEPTEMBER, 2020

INDUSTRY SYMPOSIUM
ADWP 2020:
Potential Role of ECP in Autoimmune Diseases

Virtual Event

View Symposium

31 August, 2020

NURSE SYMPOSIUM
EBMT 2020:
THERAKOS ECP Immunomodulation^TM – How and why

Virtual event

View Symposium

30 August, 2020

CLINICAL SYMPOSIUM EBMT 2020:
The role of ECP in the treatment of GvHD

Virtual event

View Symposium

22 November, 2019

6^th Nordic Photopheresis Meeting

Stockholm, Sweden

Read more

17 September, 2019

Symposium at ESOT congress

Copenhagen, Denmark

View Symposium

Visit the MedTech Europe website to download the latest updated Medical Devices Regulations.

The Therakos Institute

Discover More

Our Webinars

Discover More

Our Centres of Excellence

Discover More

Our Speaker Meetings

Discover More

Important Safety Information
For the Therakos^TM Photopheresis
Procedure

The THERAKOS^TM CELLEX^TM Photopheresis System is indicated for the administration of photopheresis. Please refer to the appropriate product labelling for a complete list of warnings and precautions.

Indications

The THERAKOS^TM CELLEX^TM Photopheresis System is indicated for the administration of photopheresis. Please refer to the appropriate product labelling for a complete list of warnings and precautions.

Contraindications

THERAKOS^TM Photopheresis is contraindicated in:

Patients exhibiting idiosyncratic or hypersensitivity reactions to 8-methoxypsoralen/psoralen compounds
Patients possessing a specific history of a light sensitive disease
Patients who cannot tolerate extracorporeal volume loss or who have white blood cell counts greater than 25,000 / mm³
Patiets who have coagulation disorders or who have previously had a splenectomy

Warnings and Precautions

THERAKOS^TM Photopheresis treatments should always be performed in locations where standard medical emergency equipment is available. Volume replacement fluids and/or volume expanders should be readily available throughout the procedure. Safety in children has not been established.

Adverse Events

Hypotension may occur during any treatment involving extracorporeal circulation. Closely monitor the patient during the entire treatment for hypotension.

Transient pyretic reactions, 37.7–38.9°C (100–102°F), have been observed in some patients within six to eight hours of reinfusion of the photoactivated leukocyte-enriched blood. A temporary increase in erythroderma may accompany the pyretic reaction.

Treatment frequency exceeding labelling recommendations may result in anaemia.

Venous access carries a small risk of infection and pain.

Please refer to the THERAKOS^TM CELLEX^TM Photopheresis System Operator Manual for a complete list of warnings and precautions.

To report an adverse event please contact us at:
INTERNATIONAL FREEPHONE: 00800 84372567 (Available from most countries in Europe and Middle East and Africa)

ecphelp@therakos.com

IMPORTANT SAFETY INFORMATION FOR METHOXSALEN USED IN CONJUNCTION WITH THERAKOS^TM PHOTOPHERESIS

Contraindications

<p class="mb-2">Methoxsalen is contraindicated in: </p> <ul class="list-disc"> <li>Patients exhibiting idiosyncratic or hypersensitivity reactions to methoxsalen, psoralen compounds, or any of the excipients</li> <li>Patients with co-existing melanoma, basal cell or squamous cell skin carcinoma</li> <li>Patients who are pregnant, and sexually active men and women of childbearing potential unless adequate contraception is used during treatment</li> <li>Patients with aphakia because of the significantly increased risk of retinal damage due to the absence of a lens</li> </ul>

Warnings and Precautions

<ul class="list-disc"> <li>Special care should be exercised in treating patients who are receiving concomitant therapy (either topically or systemically) with known photosensitizing agents.</li> <li>Oral administration of methoxsalen followed by cutaneous UVA exposure (PUVA therapy) is carcinogenic.</li> <li>Patients should be told emphatically to wear UVA absorbing, wrap-around sunglasses for twenty-four (24) hours after methoxsalen treatment. They should wear these glasses any time they are exposed to direct or indirect sunlight, whether they are outdoors or exposed through a window.</li> <li>Safety in children has not been established.</li> </ul> Patients should be told emphatically to wear UVA absorbing, wrap-around sunglasses for twenty-four (24) hours after methoxsalen treatment. They should wear these glasses any time they are exposed to direct or indirect sunlight, whether they are outdoors or exposed through a window. Safety in children has not been established. Refer to the Methoxsalen (20 micrograms/mL) labelling or the oral 8-methoxypsoralen dosage formulation package insert for more information on protecting the patient from light and a list of all warnings and precautions.

Important Safety Information
For the Therakos^TM Photopheresis
Procedure

Indications

The THERAKOS^TM CELLEX^TM Photopheresis System is indicated for the administration of photopheresis. Please refer to the appropriate product labelling for a complete list of warnings and precautions.

Contraindications

THERAKOS^TM Photopheresis is contraindicated in:

Patients exhibiting idiosyncratic or hypersensitivity reactions to 8-methoxypsoralen/psoralen compounds
Patients possessing a specific history of a light sensitive disease
Patients who cannot tolerate extracorporeal volume loss or who have white blood cell counts greater than 25,000 / mm³
Patiets who have coagulation disorders or who have previously had a splenectomy

Warnings and Precautions

THERAKOS^TM Photopheresis treatments should always be performed in locations where standard medical emergency equipment is available. Volume replacement fluids and/or volume expanders should be readily available throughout the procedure. Safety in children has not been established.

Do not expose the device to a magnetic resonance (MR) environment. The device may present a risk of projective injury, and thermal injury and burns may occur. The device may generate artifacts in the MR image, or may not function properly.
Thromboembolic events, including pulmonary embolism and deep vein thrombosis, have been reported in the treatment of Graft versus Host Disease (GvHD, an indication not approved in Canada. Special attention to adequate anticoagulation is advised when treating patients with GvHD.
When prescribing and administering THERAKOS^TM Photopheresis for patients receiving concomitant therapy, exercise caution when changing treatment schedules to avoid increased disease activity that may be caused by abrupt withdrawal of previous therapy.

Adverse Events

Hypotension may occur during any treatment involving extracorporeal circulation. Closely monitor the patient during the entire treatment for hypotension.
Transient pyretic reactions, 37.7–38.9°C (100–102°F), have been observed in some patients within six to eight hours of reinfusion of the photoactivated leukocyte-enriched blood. A temporary increase in erythroderma may accompany the pyretic reaction.
Treatment frequency exceeding labelling recommendations may result in anaemia.
Venous access carries a small risk of infection and pain.

Please refer to the THERAKOS^TM CELLEX^TM Photopheresis System Operator Manual for a complete list of warnings and precautions.

IMPORTANT SAFETY INFORMATION FOR METHOXSALEN USED IN CONJUNCTION WITH THERAKOS^TM PHOTOPHERESIS

Contraindications

Methoxsalen is contraindicated in:

Patients exhibiting idiosyncratic or hypersensitivity reactions to methoxsalen, psoralen compounds, or any of the excipients
Patients with co-existing melanoma, basal cell or squamous cell skin carcinoma
Patients who are pregnant, and sexually active men and women of childbearing potential unless adequate contraception is used during treatment
Patients with aphakia because of the significantly increased risk of retinal damage due to the absence of a lens

Warnings and Precautions

Special care should be exercised in treating patients who are receiving concomitant therapy (either topically or systemically) with known photosensitizing agents.
Oral administration of methoxsalen followed by cutaneous UVA exposure (PUVA therapy) is carcinogenic.
Patients should be told emphatically to wear UVA absorbing, wrap-around sunglasses for twenty-four (24) hours after methoxsalen treatment. They should wear these glasses any time they are exposed to direct or indirect sunlight, whether they are outdoors or exposed through a window.
Safety in children has not been established.

Refer to the package insert for methoxsalen sterile solution (20 micrograms / mL) or the oral 8-methoxypsoralen dosage formulation for a list of all warnings and precautions.